Hoorn Nh

• ATLAS trial Pending
  2024-517233-40-00 6 Perianal abscess
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• Dual-immunotherapy and short-course medium-dose radiotherapy, followed by surgery for tumor microenvironment modification in early-stage NSC … Recruiting
  2024-516580-87-00 9 2024-10-29 early stage NSCLC
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• MEtformin as a MEtabolic iNTervention in Oesophageal adenocarcinomas to improve response to neoadjuvant chemoradiotherapy Recruiting
  2024-511626-30-00 4 2025-03-09 Oesophageal adenocarcinoma
• Laparoscopic Antibiotic Lavage to Prevent intra-abdominal Abscess formation in Complicated Appendicitis (ALPACA) Recruiting
  2024-514850-59-00 5 2025-02-24 Appendicitis
• PEPPER-trial Recruiting
  2023-507763-18-01 6 2024-05-21 Placenta previa, preterm birth
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting
  2023-505221-14-00 4 2024-04-04 Multiple Myeloma
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting
  2024-513314-35-00 4 2017-01-20 Adenocarcinoma of the Colon or rectosigmoid (considered as non-rectal)
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended recruitment
  2023-504553-12-01 6 2023-12-27 Influenza
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti … Ended recruitment
  2022-501534-33-00 6 2023-03-06 Unexplained Subfertility, infertility
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma

Showing 1–24 of 34 trials